A bipartisan group of 31 senators last week urged Food and Drug Administration Commissioner Scott Gottlieb, M.D., to convene the Drug Shortages Task Force created by the FDA Safety and Innovation Act of 2012, stakeholders and other relevant agencies to report on the root causes of drug shortages and the authorities FDA and other federal agencies need to address them. “We appreciate the work of the agency to mitigate the impact of shortages created in the wake of Hurricane Maria and recent shortages resulting from manufacturing deficiencies,” the senators wrote. “However, drug shortages continue to present consistent, frequent, and significant risks for patients and threaten the stability of our health care system.” The letter was spearheaded by Senate Health, Education, Labor and Pensions Committee members Chris Murphy (D-CT) and Bill Cassidy (R-LA).
 

Related News Articles

Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.“Some of the most…
Headline
The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and…
Headline
In a statement submitted to the House Ways and Means Committee for a hearing Feb. 6 on chronic drug shortages, AHA recommended Congress enact legislation to…
Headline
Reps. Doris Matsui, D-Calif., and Larry Bucshon, R-Ind., Jan. 12 introduced a House version of the Mapping America’s Pharmaceutical Supply Act, legislation…